Coherus BioSciences Inc.

0.78
-0.04 (-4.49%)
At close: Apr 04, 2025, 3:59 PM
0.77
-1.29%
After-hours: Apr 04, 2025, 05:37 PM EDT

Coherus BioSciences Statistics

Share Statistics

Coherus BioSciences has 115.9M shares outstanding. The number of shares has increased by 1.02% in one year.

Shares Outstanding 115.9M
Shares Change (YoY) 1.02%
Shares Change (QoQ) 0.59%
Owned by Institutions (%) 56.64%
Shares Floating 111.29M
Failed to Deliver (FTD) Shares 96
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 29.79M, so 25.77% of the outstanding shares have been sold short.

Short Interest 29.79M
Short % of Shares Out 25.77%
Short % of Float 26.84%
Short Ratio (days to cover) 13.45

Valuation Ratios

The PE ratio is 5.55 and the forward PE ratio is -77.73. Coherus BioSciences's PEG ratio is -0.05.

PE Ratio 5.55
Forward PE -77.73
PS Ratio 0.59
Forward PS 0.4
PB Ratio -1.2
P/FCF Ratio -7.73
PEG Ratio -0.05
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Coherus BioSciences.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.21, with a Debt / Equity ratio of -1.75.

Current Ratio 1.21
Quick Ratio 0.96
Debt / Equity -1.75
Debt / EBITDA 3.8
Debt / FCF -11.33
Interest Coverage -4.11

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.17M
Profits Per Employee $125.03K
Employee Count 228
Asset Turnover 0.6
Inventory Turnover 1.68

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -67.9% in the last 52 weeks. The beta is 1.01, so Coherus BioSciences's price volatility has been higher than the market average.

Beta 1.01
52-Week Price Change -67.9%
50-Day Moving Average 1.04
200-Day Moving Average 1.23
Relative Strength Index (RSI) 36.59
Average Volume (20 Days) 1.95M

Income Statement

In the last 12 months, Coherus BioSciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.

Revenue 266.96M
Gross Profit 149.41M
Operating Income -111.67M
Net Income 28.51M
EBITDA 60.94M
EBIT 55.66M
Earnings Per Share (EPS) 0.25
Full Income Statement

Balance Sheet

The company has 125.99M in cash and 231.51M in debt, giving a net cash position of -105.53M.

Cash & Cash Equivalents 125.99M
Total Debt 231.51M
Net Cash -105.53M
Retained Earnings -1.55B
Total Assets 448.53M
Working Capital 68.2M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -20.44M and capital expenditures 0, giving a free cash flow of -20.44M.

Operating Cash Flow -20.44M
Capital Expenditures 0
Free Cash Flow -20.44M
FCF Per Share -0.18
Full Cash Flow Statement

Margins

Gross margin is 55.97%, with operating and profit margins of -41.83% and 10.68%.

Gross Margin 55.97%
Operating Margin -41.83%
Pretax Margin 10.68%
Profit Margin 10.68%
EBITDA Margin 22.83%
EBIT Margin -41.83%
FCF Margin -7.66%

Dividends & Yields

CHRS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CHRS is $7, which is 797.4% higher than the current price. The consensus rating is "Buy".

Price Target $7
Price Target Difference 797.4%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score -4.63
Piotroski F-Score 4